Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals is implementing Production Linked Incentive Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore
Scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years
प्रविष्टि तिथि:
02 AUG 2024 4:55PM by PIB Delhi
The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
|
S. No.
|
Name of the product
|
Usage
|
|
1
|
Nitisinone
|
Treatment of Hereditary Tyrosinemia Type 1
|
|
2
|
Nusinersen
|
Treatment of Spinal Muscular Atrophy
|
|
3
|
Rufinamide
|
Treatment of Lennox-Gastaut syndrome.
|
|
4
|
Sodium Phenyl Butyrate
|
Treatment of Urea Cycle Disorders
|
|
5
|
Tiopronin
|
Prevention of Cystine Nephrolithiasis
|
|
6
|
Trientine Hydrochloride
|
Treatment of Wilson's disease
|
|
7
|
Eliglustat
|
Treatment of Gaucher’s disease
|
|
8
|
Cannabidiol
|
Treatment of Dravet-Lennox Gastaut syndrome
|
This information was given by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Lok Sabha in reply to a question today.
*****
MV/AKS
(रिलीज़ आईडी: 2040807)
आगंतुक पटल : 3525